submitted by information 676 days ago (via accessdata.fda.gov)
In October 2007, FDA warned healthcare professionals about reports of acute pancreatitis in patients taking the antidiabetic drug Byetta (exenatide). Since then, FDA has received reports of six cases of hemorrhagic or necrotizing pancreatitis in pat...
submitted by information 676 days ago (via accessdata.fda.gov)
As the flu season approaches, FDA is urging healthcare facilities to ensure that influenza vaccination programs are available for their personnel. Vaccinating healthcare workers will decrease the likelihood that they will contract influenza, and als...
submitted by information 676 days ago (via accessdata.fda.gov)
FDA is requiring that conventional antipsychotic drugs carry a boxed warning stating that these drugs increase the risk of death when they are used to treat dementia-related psychosis in elderly patients. This category includes such drugs as Haldo...
submitted by information 676 days ago (via accessdata.fda.gov)
FDA is alerting healthcare professionals that certain patients are more likely to experience serious and potentially fatal hypersensitivity reactions when treated with the antiretroviral drug abacavir. Abacavir is sold under the trade name Ziagen an...
submitted by information 676 days ago (via accessdata.fda.gov)
FDA is reminding healthcare professionals that patients who take amiodarone along with drugs that contain simvastatin have an increased risk of rhabdomyolysis, a type of muscle injury that can lead to kidney failure and death. Amiodarone is an antia...
submitted by information 676 days ago (via accessdata.fda.gov)
An alert from the Institute for Safe Medication Practices warns about potentially fatal errors that can occur with concentrated oral opiate solutions.
ISMP cites a recent case involving an 18 year old who was prescribed oxycodone oral solution to ...
submitted by information 676 days ago (via accessdata.fda.gov)
Every year, FDA receives more than 400,000 reports of adverse events associated with the use of drugs marketed in the U.S. FDA continually reviews these reports to identify signals of potential drug risks.
The Drug Safety Newsletter is one way ...
submitted by onlinepharmacy 669 days ago (via cfsan.fda.gov)
The U. S. Food and Drug Administration (FDA) has scheduled a Nutrition Roundtable Discussion on Friday, December 12, 2008 from 1:00 until 3:30 PM, at the FDA Center for Food Safety and Applied Nutrition (CFSAN), Harvey W. Wiley Building, 5100 Paint Branch Parkway, College Park, Maryland.
